Coronavirus vaccine news update: Russia has said that it would start production of one of its COVID-19 vaccine candidates by Gamaleya Institute of Epidemiology and Microbiology in September

Russian Defence Ministry says final check-up of volunteers at Burdenko Hospital showed complete improvement in their immunity with no side-effects; vaccine is being developed by Gamaleya National Research Center of Epidemiology and Microbiology in Moscow

On July 20, 2020, the company received approval from the Drug Controller General of India (DCGI) to manufacture and market remdesivir for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19

Indian vaccine manufacturers are waiting for a vaccination plan from the government so that they can set aside stocks of vaccines when they are approved for production

Coronavirus vaccine news update: Pharmaceutical giant AstraZeneca has also said that coronavirus might require annual vaccination. CEO Pascal Soriot said that the virus is 'very unpredictable'

Coronavirus vaccine: The Russian vaccine has raised concerns because of the speed at which it is being pushed through. However, the Russian Defence Ministry clarified that tests of the vaccine against coronavirus were conducted in full compliance with methodological regulations

Russia's first potential COVID-19 vaccine, developed by a state research facility, would secure local regulatory approval in August and be administered to health workers soon after that

Under White House orders, federal health agencies and the Defense Department are carrying out a plan dubbed Operation Warp Speed to deliver 300 million vaccine doses on a compressed timeline

Pfizer is one of many companies racing to bring COVID-19 vaccines to market, seen as essential to ending a pandemic that has claimed more than 655,000 lives globally

Prof S Sadagopan, Director-IIIT, Bengaluru said BelYo would be able to simplify the tracking of all the COVID-19 patients in India - from symptoms to vaccination certificate in a decentralised manner, without compromising on the privacy of the data

While there were concerns on whether the immunity would last in the case of COVID-19 vacccines under development, the results said T-cells, which directly target and kill infected cells, were induced by the vaccine

Coronavirus vacciine update: Trials on 1,077 people showed that the vaccine, officially known as AZD1222, led to generation of antibodies and white blood cells that can fight coronavirus

The study findings could help high-risk countries with population screening, case identification, contact tracing, confirming vaccine efficacy during clinical trials, and vaccine distribution, the statement said

There were no serious side effects. But more than half the study participants reported flu-like reactions to the shots that aren't uncommon with other vaccines -- fatigue, headache, chills, fever and pain at the injection site

In India, BCG vaccination of children started in 1949. In 2019, at least 97 per cent of the 2.6 crore children received the TB vaccine. The vaccine in children prevents a simple TB from turning into a  systemic and affecting the brain and other organs

Bharat Biotech is developing the vaccine in collaboration with the ICMR. It has started human trials on its vaccine candidate, 'Covaxin', which is India's first indigenous COVID-19 vaccine. It is working to develop an initial capacity of 200 million vials of the vaccine

Coronavirus vaccine news update: Serum Institute of India that is producing around four vaccine candidates including the Oxford University-AstraZeneca coronavirus candidate has said that it is expected to launch a candidate by the end of six months

A Vigyan Prasar article claimed that none of the coronavirus vaccines under development around the world, including India, would be available for mass use before 2021; PIB omitted this warning while carrying this article on its portal

PM Modi Speech on Unlock 2.0, Coronavirus and India-China Tensions Live: PM Gareeb Kalyan Anna Yojana will be extended till the end of November, extension to cost over Rs 90,00 crore, says Prime Minister Narendra Modi

The Ad5-nCoV is one of China's eight vaccine candidates approved for human trials at home and abroad for the respiratory disease caused by the new coronavirus. The shot also won approval for human testing in Canada